[1]朱红俊,苏伟,韩瑶瑶,等.化浊祛痰法对冠心病患者临床疗效及免疫机制的影响[J].西部中医药,2021,34(05):65-69.[doi:10.12174/j.issn.2096-9600.2021.05.17]
　ZHU Hongjun,SU Wei,HAN Yaoyao,et al.Clinical Effects of Resolving Turbidity Eliminating Phlegm Method in Treating the Patients with CHD and Its Influence on Immune Mechanism[J].Western Journal of Traditional Chinese Medicine,2021,34(05):65-69.[doi:10.12174/j.issn.2096-9600.2021.05.17]
点击复制

化浊祛痰法对冠心病患者临床疗效及免疫机制的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年05期
页码:
65-69
栏目:
博士论坛
出版日期:
2021-05-15

文章信息/Info

Title:
Clinical Effects of Resolving Turbidity Eliminating Phlegm Method in Treating the Patients with CHD and Its Influence on Immune Mechanism
作者:
朱红俊, 苏伟, 韩瑶瑶, 周春刚
南京中医药大学无锡附属医院，江苏 无锡 214001
Author(s):
ZHU Hongjun, SU Wei, HAN Yaoyao, ZHOU Chungang
Wuxi Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Wuxi 214001, China
关键词:
冠心病; 免疫功能; 化浊祛痰法; 临床疗效
Keywords:
CHD; immune function; resolving turbidity eliminating phlegm method; clinical effects
分类号:
R541
DOI:
10.12174/j.issn.2096-9600.2021.05.17
摘要:
目的探讨化浊祛痰法对冠心病痰浊证患者临床疗效及淋巴细胞亚群分布的影响。 方法将冠心病痰浊证患者74例随机分为对照组和治疗组各37例，另设健康组39人。对照组采用标准化冠心病治疗方案，治疗组在对照组基础上加用化浊祛痰方治疗。观察两组临床疗效及淋巴细胞亚群等免疫学指标变化情况。 结果1）中医证候疗效方面，总有效率治疗组为94.6%（35/37），高于对照组的86.5%（32/37），差异有统计学意义（P＜0.05）；西雅图心绞痛量表积分方面，治疗组AS、AF积分高于对照组，差异具有统计学意义（P＜0.05）。2）两组白细胞CD45，淋巴细胞CD3、CD4、CD19、CD192，单核细胞CD14均高于健康组；而淋巴细胞CD8，NK细胞CD16/CD56，单核细胞CD192低于健康组，差异具有统计学意义（P＜0.05）。3）两组患者免疫功能均改善。其中治疗组在白细胞CD45，淋巴细胞CD3、CD8、CD192，单核细胞CD192的下降和淋巴细胞CD4、CD19、CD192，NK细胞CD16/CD56，单核细胞CD14的上升方面优于对照组，差异具有统计学意义（P＜0.05）。 结论化浊祛痰法提高痰浊证冠心病患者临床疗效的机制可能与调节免疫功能有关。
Abstract:
ObjectiveTo explore clinical effects of resolving turbidity eliminating phlegm method in treating coronary heart disease（CHD） of phlegm turbidity pattern and its influence on the distribution of lymphocyte subsets. MethodsAll 74 patients were randomized into the control group and the treatment group, 37 cases in each group, and 39 persons of the healthy group was established. The control group adopted standardized treatment of CHD, and the treatment group took resolving turbidity eliminating phlegm prescription based on standardized treatment of CHD. To observe clinical efficacy, the changes of lymphocyte subsets and other immunological indexes between both groups. Results1)Curative effects of TCM syndromes, total effective rate of the treatment group was 94.6%（35/37）, higher than 86.5%（32/37） of the control group, and the difference had statistical meaning (P<0.05); on the scores of Seattle Angina pectoris scales, the treatment group was higher than the control group in AS and AF scores, and the difference was statistically significant (P<0.05). 2) The control group and the treatment group were higher than the healthy group in the levels of leucocyte CD45, lymphocytes CD3, CD4, CD19, CD192 and monocyte CD14; while lower than the healthy group in lymphocyte CD8, NK cells CD16/CD56 and monocyte CD192, and the difference showed statistical meaning (P<0.05). 3)The immune functions of the control group and the treatment group were improved, among them, the treatment group was superior to the control group in the decrease of leucocyte CD45, lymphocytes CD3, CD8, CD192 and monocyte CD192, the rise of lymphocytes CD4, CD19, CD192, NK cells CD16/CD56 and monocyte CD14, and the difference had statistical meaning (P<0.05). ConclusionThe mechanism of resolving turbidity eliminating phlegm method improving clinical effects of CHD patients might be related to regulating immune function.

相似文献/References:

[1]马思清 指导：谢春毅.瓜蒌薤白三方防治冠心病的研究现状[J].西部中医药,2012,25(10):118.
　MA Si-qing Director: XIE Chun-yi.Exploration on Three Pieces of GuaLou XieBaiFang in the Prevention of Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2012,25(05):118.
[2]杨宏权,贡布东智△,刘玉玲,等.藏药制剂康速能补胶囊的药效学研究[J].西部中医药,2012,25(08):53.
　YANG Hong-quan,GONG BU Dong-zhi,LIU Yu-ling,et al.Pharmacodynamics of Tibetan Agent KangSu NengBu Capsule[J].Western Journal of Traditional Chinese Medicine,2012,25(05):53.
[3]潘雪晖.综合护理干预对冠心病患者不良生活方式的影响[J].西部中医药,2013,26(07):105.
　PAN Xuehui.Impact of Comprehensive Nursing Intervention on Lifestyles of Patients with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(05):105.
[4]袁春玲.家庭病床冠心病护理可行性探讨[J].西部中医药,2012,25(07):109.
　YUAN Chun-ling.Probe into Feasibility of Nursing for Patients with Coronary Heart Disease in Family Practice[J].Western Journal of Traditional Chinese Medicine,2012,25(05):109.
[5]王凯,林文.丹红与丹参酮ⅡA治疗冠心病心绞痛疗效比较[J].西部中医药,2013,26(08):88.
　WANG Kai,LIN Wen.Comparison between DanHong Injection and Tanshinone ⅡA in Treating Angina Pectoris of Patients with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(05):88.
[6]赵云霞,刘正跃.综合护理干预对冠心病患者不良生活方式的影响[J].西部中医药,2012,25(05):105.
　ZHAO Yun-xia,LIU Zheng-yue.Effects of Comprehensive Nursing Intervention on Unhealthy Lifestyle of Patients with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2012,25(05):105.
[7]王瑞福.调脂汤对冠心病PCI术后血液流变学及血脂的影响[J].西部中医药,2013,26(12):71.
　WANG Ruifu.Effects of TiaoZhi Tang on Blood Lipid and Rheology of the Patients with Coronary Heart Disease After PCI[J].Western Journal of Traditional Chinese Medicine,2013,26(05):71.
[8]孙文,谢春毅△.丹红注射液治疗冠心病心绞痛临床观察[J].西部中医药,2014,27(03):5.
　SUN Wen,XIE Chunyi.Clinical Observation on DanHong Injection in Treating Coronary Heart Disease Angina Pectoris[J].Western Journal of Traditional Chinese Medicine,2014,27(05):5.
[9]付伟光,齐振勇,李爱军,等.HCY、HS-CRP、LP(a)及 D- 二聚体联合检测在冠心病病程中动态检测意义的研究*[J].西部中医药,2014,27(08):148.
[10]张丽君,赵江花,赵海红,等.心脉疏膏穴位贴敷结合西药治疗冠心病心绞痛 40 例[J].西部中医药,2014,27(09):128.

备注/Memo

备注/Memo:
朱红俊（1976—），男，博士学位，主任医师。研究方向：心血管系统疾病的中西医结合防治。江苏省第十三批“六大人才高峰”项目C类资助项目（WSN-244）。
更新日期/Last Update: 2021-05-15